P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
B.C. Cho, D.-W. Kim, J.-Y. Han, J.-S. Lee, E.K. Cho, K.H. Lee, J.M. Bauml, M. Thayu, J.C. Curtin(Janssen (United States)), R.W. Schnepp, G. Gao, S.-H. Lee(Samsung Medical Center), R.E. Knoblauch, J. Xie
Cited by 7
Related Papers
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
|Annals of Oncology|2024|81
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
|ESMO Open|2023|16
MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
|Journal of Thoracic Oncology|2022|4
MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
|Journal of Thoracic Oncology|2023|4
OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
|Journal of Thoracic Oncology|2023|1